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Abstract
The emergence of Staphylococcus aureus strains resistant to 'last resort' antibiotics compels the
development of new antimicrobials against this important human pathogen. We found that propyl
5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC) shows bacteriostatic activity against
S. aureus (MIC = 4 μg/ml) and rescues Caenorhabditis elegans from S. aureus infection. Whole-genome
sequencing of S. aureus mutants resistant to the compound, along with screening of a S. aureus
promoter-lux reporter array, were used to explore possible mechanisms of action. All mutants resistant to
HMPC acquired missense mutations at distinct codon positions in the global transcriptional regulator
mgrA, followed by secondary mutations in the phosphatidylglycerol lysyltransferase fmtC/mprF. The S.
aureus promoter-lux array treated with HMPC displayed a luminescence profile that was unique but
showed similarity to DNA-damaging agents and/or DNA replication inhibitors. Overall, HMPC is a new
anti-staphylococcal compound that appears to act via an unknown mechanism linked to the global
transcriptional regulator MgrA.
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Propyl-5-hydroxy-3-methyl1-phenyl-1H-pyrazole-4carbodithioate (HMPC): a
new bacteriostatic agent
against methicillin—resistant
Staphylococcus aureus
Tatiana Johnston1, Daria Van Tyne2,3, Roy F. Chen1, Nicolas L. Fawzi
Michael J. Kelso 6, Michael S. Gilmore2,3 & Eleftherios Mylonakis1

4

, Bumsup Kwon5,

The emergence of Staphylococcus aureus strains resistant to ‘last resort’ antibiotics compels the
development of new antimicrobials against this important human pathogen. We found that propyl
5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC) shows bacteriostatic activity
against S. aureus (MIC = 4 μg/ml) and rescues Caenorhabditis elegans from S. aureus infection. Wholegenome sequencing of S. aureus mutants resistant to the compound, along with screening of a S. aureus
promoter-lux reporter array, were used to explore possible mechanisms of action. All mutants resistant
to HMPC acquired missense mutations at distinct codon positions in the global transcriptional regulator
mgrA, followed by secondary mutations in the phosphatidylglycerol lysyltransferase fmtC/mprF. The
S. aureus promoter-lux array treated with HMPC displayed a luminescence profile that was unique but
showed similarity to DNA-damaging agents and/or DNA replication inhibitors. Overall, HMPC is a new
anti-staphylococcal compound that appears to act via an unknown mechanism linked to the global
transcriptional regulator MgrA.
Staphylococcus aureus is a highly adaptive human pathogen that is responsible for a variety of diseases ranging
from soft tissue infections to bacteremia, endocarditis, pneumonia and osteomyelitis1–3. According to a report
from the US Centers for Diseases Control, the resistance of S. aureus to methicillin and related beta-lactams, as
well as to cephalosporins poses a large concern for public health. The CDC reported that methicillin-resistant
S. aureus (MRSA) alone was responsible for 80,461 invasive infections and 11,285 related deaths in 20114. The
organism possesses a remarkable ability to survive by adapting to changing environmental conditions and by
mobilizing complex defense mechanisms in response to exogenous stressors5. The overuse of antibiotics in medicine and agriculture, together with the use of compounds that target essential cellular functions, such as DNA
replication, RNA transcription and protein and cell wall synthesis, have put selective pressure on bacteria leading
to multidrug-resistant strains that are both challenging and expensive to treat6–8. The loss of potency of antibiotics to treat S. aureus infections poses a serious threat to public health, as evidenced by the emergence of
methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) strains9–12. The resistance
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of S. aureus to ‘last resort’ antibiotics (vancomycin, and more recently daptomycin and linezolid) has placed this
bacterium on the World Health Organization’s list of high priority antibiotic-resistant bacteria for which there is
an urgent need to develop effective new treatments13.
In this study, we describe the antimicrobial properties of propyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole4-carbodithioate (HMPC) as a new agent against S. aureus and suggest that it likely acts via a novel mechanism
of action.

Results

Antimicrobial activity. Screening of the Maybridge 5 Library (Maybridge, Thermo Fisher Scientific) identified HMPC as a compound with direct inhibitory activity against S. aureus MW2 (MIC = 4 μg/ml, Fig. 1A)14
and the ability to rescue C. elegans from S. aureus MW2 infection15–18, with the fraction of C. elegans survival
ranging between 93–100% after 5 days of co-incubation (Fig. 1B–D). HMPC appeared to not affect the viability
of C. elegans at the screening concentration of 7 μg/ml. The compound was found to be equipotent across a panel
of recent clinical isolates of methicillin-resistant S. aureus from our laboratory collection, where all tested isolates
had MICs = 4 μg/ml (Table 1).
The spectrum of activity of HMPC was evaluated by determining its MIC against a panel of ESKAPE
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter species) pathogens19,20. In addition to S. aureus, the compound was also found to be
active against Enterococcus faecium (MIC = 16 μg/ml), but showed no activity against the gram-negative strains
tested (Table 2). Growth curves of the S. aureus MW2 strain in the presence of increasing concentrations of
HMPC showed that the compound was able to inhibit growth in a concentration-dependent manner over the
range 1–4 μg/ml (Fig. 2A). We also performed a time-kill assay using a high concentration of HMPC (16 μg/ml,
4xMIC) and compared the killing kinetics of HMPC to the rapidly bacteriocidal antibiotic daptomycin (Fig. 2B).
We found that HMPC did not cause a reduction in bacterial viability until eight hours post-treatment, in contrast
to the rapidly bacteriocidal nature of treatment with daptomycin.
Screening of a S. aureus promoter-lux clone array. Antibiotic-activated promoter-lux clone arrays
in S. aureus provide characteristic transcriptional activation light signatures that can be used to discriminate
between different antibiotic classes based on their mechanism(s) of action21. We screened a promoter-lux array
to investigate whether HMPC induces transcriptional changes in S. aureus similar to those of known classes of
antibiotics. HMPC was found to activate promoter-lux clones C, E, F, G, K, L and M (Fig. 3A), which appears to
be a unique profile but shows some overlap with DNA-damaging agents and/or DNA replication inhibitors21,22.
To test whether HMPC interacts directly with DNA, we first looked for evidence of binding in vitro by examining the UV visible spectra of HMPC in the absence or presence of excess calf thymus DNA (Fig. S1). No DNA
hyperchroism or hypochromism was observed, nor were any shifts in positions of absorption bands in the region
290–360 nm, suggesting that HMPC does not interact with eukaryotic DNA. We confirmed this observation by
measuring the zones of S. aureus growth inhibition produced by different concentrations of the compound in
the presence or absence of excess calf thymus DNA (Fig. 3B). The insignificant 3 mm inhibition zone decrease
was observed in the presence of calf thymus DNA, suggesting that HMPC does not tightly bind to DNA. To test
whether the compound binds to S. aureus DNA, we conducted disc diffusion assays using varying concentrations
of HMPC with and without S. aureus MW2 genomic DNA (Fig. 3C). A consistent decrease in the size of the inhibition zone when DNA is included was observed across HMPC concentrations, but the effect was very small and
was not statistically significant. Finally, we conducted an electrophoretic mobility shift assay (EMSA) on S. aureus
DNA incubated with HMPC or DMSO solvent alone, which did not show evidence of direct binding (Fig. S2).
The unique promoter-lux profile produced by HMPC therefore supports it being the prototypical member of a
new antibiotic class that acts via a novel mechanism. Mesak et al. postulated that new compounds could potentially produce new promoter-lux profiles21 which may apply to HMPC. Additionally, the S. aureus RN4220 strain
used to created the promoter-lux array possesses mutations that affect the virulence and fitness of the strain,
which could influence the screening results of novel compounds23.
Isolation and whole-genome sequencing of HMPC-resistant mutants. Single-step resistance selec-

tion, whereby S. aureus MW2 bacteria were plated onto 2x and 4x MIC, produced no HMPC-resistant bacteria
(data not shown); sequential passaging in liquid medium with increasing concentrations of HMPC, however,
allowed for the selection of low-level resistant mutants24. Mutant populations with increased MICs of either 8 μg/
ml or 16 μg/ml HMPC were confirmed following several passages in non-selective medium. Three independent resistance selections were conducted and whole genome sequences were obtained from controls and corresponding mutants with MICs of 8 μg/ml or 16 μg/ml (a total of 9 populations sequenced; Table 3). Analysis of
high-frequency mutations identified two genes that were repeatedly and independently mutated across multiple
selections: the transcriptional regulator mgrA (MW0648) and the phosphatidylglycerol lysyltransferase fmtC/
mprF (MW1247). Further analysis of low-frequency mutants in all selected strains revealed additional mutations in both mgrA and fmtC (Table 3). One selected strain also acquired a mutation in a hypothetical protein
(MW0910) containing a YdiL-like membrane protease domain.
We next tried to understand how the observed mutations might impact the mechanism of HMPC action
and resistance. The most often mutated gene, mgrA, is a transcriptional regulator that controls the expression
of a large number of S. aureus genes25,26. The dominant mutations observed all reside within the winged helix
DNA-binding domain of the MgrA protein (Val55Phe is at the start of α-helix 3, Pro71Gln is at the start of
α-helix 4 and Arg84His is in a β-strand of the wing region (PDB: 2PV6) (Fig. 4). Two resistant mutants contained
a single mutation in mgrA, while the remaining strains possessed subpopulations of different mutants, all of
SCIENtIfIC ReporTs | (2018) 8:7062 | DOI:10.1038/s41598-018-25571-w
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Figure 1. HMPC rescues C. elegans from MRSA infection. (A) Chemical structure of propyl 5-hydroxy-3methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC). (B–D) Results of compound screening for C. elegans
viability following S. aureus MW2 infection. A 384-well assay plate was co-inoculated with C. elegans, S. aureus
MW2 and either 7 μg/ml HMPC (B); 100% survival), 10 μg/ml vancomycin (C) positive control; 100% survival),
or 1% DMSO vehicle (D) negative control; 40% survival). Representative Sytox Orange-stained (right) and
bright field (left) images from assay wells are shown. Only dead worms take up Sytox Orange and fluoresce.
The images were first captured with an ImageExpress and further processed with CellProfiler to normalize the
fluorescent or bright field intensity and to define the area of each worm.

which are predicted to disrupt protein function (Fig. 4 and Table 3). To test whether MgrA disruption directly
impacts susceptibility to HMPC, two previously generated S. aureus MW2 mutants lacking a functional mgrA
(AH3456 and AH4322) were tested for resistance to HMPC27,28. While no difference in MIC was observed in
either mutant relative to the wild type MW2 strain AH843, both mutants were able to grow to a higher cell density
at sub-MIC levels of HMPC (Fig. S3).
All three HMPC-resistant populations also developed mutations in the phosphatidylglycerol lysyltransferase fmtC/mprF (MW1247), and these mutations were correlated with higher resistance to the compound
(MIC = 16 μg/ml; Table 3). No fmtC deletion mutant exists in the MW2 strain background, but a readily available fmtC mutant strain was identified in the Nebraska Transposon Mutant Library (NTML, mutant NE1360,
SAUSA300_1255). The fmtC transposon mutant showed a 2-fold increase in the MIC of HMPC compared to the
wild type USA300 JE2 strain (MIC = 4 μg/ml; experiments were repeated twice with triplicates or duplicates).
One resistant mutant also carried a mutation in MW0910, a hypothetical protein that contains a domain similar
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S. aureus
strain

HMPC
MIC (µg/ml)

Oxacillin
MIC (µg/ml)a

Vancomycin
MIC (µg/ml)b

BFSA25

4

32

2

BFSA30

4

32

1

BFSA31

4

64

2

BFSA32

4

64

2

BFSA33

4

64

2

BFSA48

4

>64

1

Table 1. Activity of HMPC against methicillin-resistant S. aureus (MRSA) clinical isolates. a,bMIC values for
oxacillin and vancomycin are shown for comparison.

Pathogen

HMPC, MIC
(μg/ml)

Vancomycin,
MIC (μg/ml)

Enterococcus faecium E007

16

1–2

Staphylococcus aureus MW2

4

1

Gentamicin,
MIC (μg/ml)

Klebsiella pneumoniae WGLW2

>64

0.5

Acinetobacter baumannii ATCC 17978

>64

1

Pseudomonas aeruginosa PA14

>64

2–4

Enterobacter aerogenes Hormaeche and
Edwards ATCC 13048

>64

1

Table 2. Activity of HMPC against a panel of ESKAPE pathogens. Vancomycin and gentamicin were included
for comparison purposes.

to the YdiL membrane protease. The corresponding NTML mutant (NE841, SAUSA300_0932) showed no change
in MIC compared to the wild type strain (MIC = 4 μg/ml).
The changes that occur in the transcriptional profile of S. aureus upon inactivation or overexpression of MgrA
are well established26. As a transcriptional regulator, MgrA mediates autolysis in S. aureus29,30. We tested our
MgrA mutants for autolytic activity and found that the Val55Phe mutant behaved similarly to the wild type strain,
whereas the Arg84His mutant showed increased sensitivity to treatment with Triton X-100 but was less sensitive
than the mgrA null mutants (Fig. 5A).

Mammalian cell toxicity assay. As a preliminary assessment of the selectivity of HMPC for bacterial cells

over mammalian cells, we performed a hemolysis assay with human red blood cells. HMPC showed no hemolytic
activity over the concentration range tested 0.125–64 μg/ml (Fig. 6A). We also assessed the cytotoxicity of HMPC
towards HKC-8 kidney cells (Fig. 6B) and found that an approximately 50% reduction in cell viability occurred at
concentrations close to its MIC against S. aureus MW2. However, HepG2 liver cells were less sensitive to HMPC,
with 94% survival at 4 μg/ml and then a decrease to an approximately 50% survival at 16 μg/ml (Fig. 6C). A
detailed structure activity analysis of HMPC by replacing or adding modifications to the structural components
of the compound and assessing the tradeoffs between toxicity and antimicrobial activity could potentially yield a
less toxic analog, which could be used as a prototype lead for development of new antimicrobial agents.

Discussion

New antibiotics are urgently needed to combat the growing threat posed by multidrug-resistant strains of S.
aureus. We identified HMPC, a novel anti-staphylococcal compound in the Maybridge 5 screening library, as
an antimicrobial agent that inhibited S. aureus growth and rescued C. elegans from MRSA infection15. Here we
evaluate the mode of action of HMPC, employ a promoter-lux reporter array and whole-genome sequencing of
S. aureus mutants resistant to HMPC in order to identify possible mechanisms of action, and evaluate the toxicity
of HMPC to mammalian cells and Galleria mellonella (see Supplementary Fig. S4).
Screening of a S. aureus promoter-lux array with HMPC revealed a unique transcriptional activation profile
for this compound. The compound activated promoter-lux clones C, E, F, G, K, L and M, a profile that shows some
overlap with DNA-damaging agents (overlapping activation of C, E, F, K, L, M and non-activation of J) and/or
DNA replication inhibitors (overlapping activation of C, G, K, L, M and non-activation of J). Because HMPC is
a compound with previously unknown antibacterial properties with some overlap to DNA-damaging agents, we
tested whether HMPC can directly bind DNA”. However, we did not observe tight binding to calf thymus DNA
or genomic DNA from S. aureus MW2 in a UV-visible spectra experiment, disc diffusion assay, or electrophoretic mobility shift assay. The promoter-lux clones C, E, and to a lesser extent clone F, all of which were activated
by HMPC, encode recA-lux. We evaluated whether a recA mutant strain might show altered susceptibility to
HMPC. However, the MIC of HMPC remained unchanged (MIC = 4 μg/ml) against the S. aureus JE2 strain and
its isogenic mutant lacking a functional RecA protein (NTML, NE805, SAUSA300_1178)31,32. The absence of a
difference in MIC could further suggest that the SOS response was not due to DNA damage in vivo, but rather
triggered by a different stressor. It is known, for example, that β-lactam antibiotics trigger SOS responses by compromising the integrity of the bacterial membrane, and SOS induction promotes the appearance of mutations
SCIENtIfIC ReporTs | (2018) 8:7062 | DOI:10.1038/s41598-018-25571-w
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Figure 2. (A) S. aureus MW2 growth inhibition in the presence of 1–4 μg/ml HMPC. Bacterial culture aliquots
were periodically taken during log-phase growth to measure the optical density at 600 nm (OD600). Data show
the mean +/− standard deviation of triplicate values, and significant differences from the control were observed
for all concentrations tested (p < 0.05 by two-tailed t-test). (B) Killing assay with HMPC or daptomycin (DAP).
Log-phase cultures were treated with 16 μg/ml of HMPC (4xMIC) or 10 μg/ml DAP and were incubated at 37 °C
with shaking at 220 rpm. Bacterial survival was monitored after 2, 4, 8, and 24 hours by dilutional plating and
enumeration of CFU/ml at each time point. The differences between HMPC and DAP are significant at all time
points except T0 (p < 0.05 by two-tailed t-test).

needed for the development of resistance33. We tested whether sub-MIC concentrations of HMPC increased the
frequency of spontaneous mutations that give rise to rifampicin resistance, but observed no difference between
HMPC-treated and untreated bacteria (0.309×1011 untreated versus 0.324×1011 treated). An Ames test also indicated no potential mutagenicity of HMPC (Table S1). Therefore it appears that despite its lux-array profile resembling that of DNA-damaging and SOS-inducing agents, HMPC acts via a distinct mechanism.
Whole-genome sequencing of HMPC-resistant mutants identified two genes that were repeatedly and independently mutated in response to HMPC pressure: the transcriptional regulator mgrA (MW0648) and the phosphatidylglycerol lysyltransferase fmtC/mprF (MW1247). MgrA is a global transcription regulator that belongs
to the MarR (multiple antibiotic resistance regulator)/SarA (staphylococcal accessory regulator A) family of
proteins, which respond to various environmental stressors and play a role in the development of drug resistance8,34–37. MgrA affects the expression of approximately 350 genes that control multiple properties of S. aureus,
such as expression of virulence factors, regulation of autolysis and antibiotic resistance, as well as other global
regulatory genes25,26,29,38–40. MgrA also regulates the multidrug-resistance (MDR) efflux pumps NorA, NorB
and NorC, the non-MDR efflux pump Tet38, and the ABC transporter AbcA in S. aureus. These pumps typically provide the first line of bacterial defense against antibiotics until more efficient resistance mechanisms can
emerge41,42. To test whether drug efflux was playing a role in HMPC resistance, we conducted MIC assays in the
presence of the efflux pump inhibitor thioridazine41,43. The inhibitor was found to have no effect on S. aureus susceptibility to HMPC with MIC value remaining at 4 μg/ml, suggesting that drug efflux is not a major contributor
to HMPC resistance.
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Figure 3. Response of the S. aureus promoter-lux array to HMPC treatment. (A) Results of promoter-lux
array screening. The name of each reporter clone is shown in the upper left corner of each picture. A clear
zone around the disc indicates inhibition of growth in the presence of higher concentrations of HMPC. At the
periphery of the inhibition zone, where sub-MIC levels of HMPC are present, changes in luminescence indicate
altered transcription. The disc on the left is HMPC and on the right of each panel is a DMSO (vehicle) control.
(B) Zones of S. aureus growth inhibition produced by HMPC in the presence or absence of calf thymus DNA.
Decreasing quantities of HMPC (25–5 μg) were incubated with either 5 μg calf thymus DNA or TE buffer
(control) before being spotted onto discs and placed onto agar plates containing S. aureus MW2 bacterial lawns.
(C) Disc diffusion assay with varying concentrations of HMPC in the absence or presence of S. aureus genomic
DNA. HMPC was incubated without or with 5 μg of S. aureus genomic DNA and was then applied to a filter
paper disc and placed onto a TSA plate containing S. aureus MW2 bacteria in a soft agar overlay. After overnight
incubation at 37 °C, zones of inhibition were measured with a ruler. Bars show mean values +/− standard
deviation of three independent assays, and no differences are statistically significant.

Clues as to the possible effects of the MgrA mutations that arose in the HMPC-resistant populations could
be gathered by assessing their location in the crystal structure of the protein44. The Val55Phe and Arg84His variants would clearly introduce steric clashes in the ß-strands near wing 1, a DNA-binding region of the canonical
winged-helix domain, which cannot be accommodated without changes to the overall protein structure (Fig. 4).
The Pro71Gln mutation maps to the beginning of DNA-recognition helix 4, which would cause extension of
the helix and alter the structure of the DNA-binding domain. We predict that the resistance-associated mutations we identified affect the DNA-binding winged-helix domain and thus alter the affinity of MgrA for specific
DNA-binding sites, leading to transcriptional changes in the resistant bacteria. The precise nature of these expression changes remains to be explored.
We propose that mutations in MgrA alter the expression of MgrA-regulated genes in response to HMPC, leading to adaptive responses that affect the susceptibility of S. aureus and allow other, more stable resistance mutations to appear. This hypothesis was supported by the appearance of secondary mutations in fmtC (MW1247)
during the course of the resistance selection experiment. FmtC, also referred to as multiple peptide resistance factor (MprF)45, catalyzes the formation of lysyl-phosphatidylglycerol during lipid biosynthesis, a modification that
SCIENtIfIC ReporTs | (2018) 8:7062 | DOI:10.1038/s41598-018-25571-w
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Selection

MIC (μg/ml) MW2 pos (bp) Typea

Length (bp)

Gene ID

Frequency (%)

Protein changeb

1

8

731157

MNV

17

MgrA

46.8

G108fs

731244

SNV

1

MgrA

51.9

R84H

2

8

731332

SNV

1

MgrA

100

V55F

3

8

731158

Deletion

12

MgrA

52.9

L109del4

731283

SNV

1

MgrA

28.9

P71N

731470

SNV

1

MgrA

10.5

E9*

731244

SNV

1

MgrA

100

R84H

1366975

Deletion

4

FmtC

93.5

I461fs

731295

SNV

1

MgrA

20.9

G67A

731332

SNV

1

MgrA

77.4

V55F

1366139

Deletion

7

FmtC

28

I181fs

731283

SNV

1

MgrA

100

P71N

1005808

Insertion

1

Hyp YdiL

85

L151fs

1366760

Deletion

684

FmtC

100

N386del228

1
2

3

16
16

16

Table 3. Mutations identified in HMPC-resistant S. aureus mutants selected in vitro. aMNV = Multi-nucleotide
variant; SNV = Single Nucleotide Variant. bfs = frame-shift; *stop codon.

Figure 4. HMPC resistance-associated mutations in MgrA map to the DNA-binding domain. The MgrA dimer
(PDB: 2BV6) is shown with the two equivalent subunits colored light blue and white/grey. Missense variants at
Val55, Pro71, and Arg84 (shown in red) are all found in the winged-helix DNA-binding domain (left, bottom
half), including in the DNA recognition helix. Image created in PyMOL with Flaticon.

Figure 5. Autolysis assay for HMPC-resistant mutants containing Val55Phe and Arg84His mutations in MgrA.
Bacteria were grown in a 96-well plate at 37 °C without shaking and optical density at 600 nm (OD600) was
measured hourly. The strains AH843, AH3456, and AH3422 were included as controls. The experiment was
repeated twice with triplicates for each strain. Data show the mean +/− standard deviation, and p < 0.001 by
one-way RM ANOVA 5 followed by Student-Newman-Keuls method.
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Figure 6. Mammalian cell toxicity assays. (A) HMPC hemolysis assay. Red blood cells were diluted to 2% with
PBS and then incubated with HMPC over the concentration range 0.125−64 μg/ml. (B) Cytotoxicity of HMPC
towards HKC-8 cells. HKC-8 cells were treated with increasing concentrations of HMPC for 24 hours before
assessing viability using a WST-1 assay. (C) Cytotoxicity of HMPC towards HepG2 cells. HepG2 cells were
treated with increasing concentrations of HMPC for 24 hours before assessing viability using a WST-1 assay. All
experiments were repeated twice in triplicate and data show the mean +/− standard deviation.

increases cell surface positive charge and confers protection against cationic antibiotics46–50. It has been suggested
that MprF plays a biophysical role in membrane stability and organization, and that this can modify S. aureus
susceptibility to antibiotics47,51. A change in membrane organization that reduces HMPC entry into bacterial cells
would explain the increased resistance we observed in the S. aureus JE2 fmtC mutant strain. In conclusion, neither
of the resistance-associated genes we identified is likely to be the cellular target of HMPC. Thus further studies are
needed to determine the precise mechanism of action of this compound.
Overall, we report a novel bacteriostatic agent that effectively inhibits the growth of drug-resistant S. aureus.
While the mechanism of action of HMPC remains unknown, we postulate that it acts on multiple targets within
the bacterial cell to induce a stress response, which can be mitigated by transcription changes driven by mutations
in MgrA. These changes are followed by a rise in more specific mutations that affect the cellular membrane and
possibly reduce entry of HMPC into S. aureus cells. Future work will focus on the synthesis of structural analogs
that retain anti-staphylococcal activity but are less toxic to mammalian cells.
SCIENtIfIC ReporTs | (2018) 8:7062 | DOI:10.1038/s41598-018-25571-w
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Species

Strain name

Staphylococcus aureus, MRSA

MW2 (laboratory collection)

Staphylococcus aureus,MRSA

AH843, MW2 (Horswill laboratory)

Staphylococcus aureus, MRSA

USA300 JE2 (Department of Pathology and Microbiology, University of Nebraska)

Staphylococcus aureus JE2 mutants

Nebraska Transposon Mutant Library (BEI Resources)

Staphylococcus aureus,MRSA

AH3456, MW2 ∆mgrA::tetM (Horswill laboratory)

Staphylococcus aureus,MRSA

AH3422, MW2 ∆mgrA (Horswill laboratory)

Staphylococcus aureus MgrA mutant

MW2, R84H mutation in MgrA

Staphylococcus aureus MgrA mutant

MW2, V55H mutation in MgrA

Enterococcus faecium

E00760

Klebsiella pneumoniae

WGLW2 (HM-751, BEI Resources)

Acinetobacter baumannii

ATCC 17978

Enterobacter aerogenes Hormaeche and Edwards ATCC 13048
Pseudomonas aeruginosa

PA1461

Staphylococcus aureusclinical isolates, MRSA

BFSA25, BFSA30, BFSA31, BFSA32, BFSA33, BFSA48, BFSA49, BFSA50, BFSA51
(Mylonakis laboratory collection)

Table 4. Bacterial strains used in this study.

Materials and Methods

Bacterial strains and media. The bacterial strains used in this study are listed in Table 4. Bacterial cultures
were grown either in Mueller-Hinton Broth (MHB) (212322, BD Biosciences, MD, USA) or Bacto Tryptic Soy
Broth (TSB) (21825, BD Biosciences, MD, USA) liquid medium or on solid agar plates (05040, Agar powder for
microbiology, Sigma-Aldrich, MO, USA). The growth of bacterial clones and screening of the S. aureus promoter-lux array were performed using NYE medium supplemented with 10 μg/ml chloramphenicol (NYEC)52.
Minimum inhibitory concentration, dose response, and antimicrobial killing assays. Propyl
5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC) was purchased from Fisher HealthCare
(Thermo Fisher Scientific, TX, USA). The compound was dissolved in 100% DMSO at a concentration of 5 mg/
ml. The MIC was determined by a two-fold broth microdilution procedure in 96-well plates in MHB according
to standard methods53. Dose-response curves were generated by measuring optical density (OD600) of the MIC
plate after 24 hours of growth using a Synergy plate reader and Gen5 software (Biotek Instruments, VT, USA).
For antimicrobial killing assays, log-phase cultures (OD600 = 0.3) grown in MHB were treated with 16 μg/ml of
HMPC (4xMIC) or 10 μg/ml daptomycin and were incubated at 37 °C with shaking at 220 rpm. Bacterial survival
was monitored after 2, 4, 8, and 24 hours by dilutional plating and enumeration of CFU/ml at each time point.
Growth inhibition of S. aureus MW2 by HMPC. An overnight culture of S. aureus MW2 was diluted
into MHB containing HMPC at varying concentrations and the bacteria were grown at 37 °C for 24 hours. DMSO
was used as vehicle control. Bacterial culture aliquots were periodically drawn to measure the optical density at
600 nm (OD600) on an Eppendorf BioPhotometer Plus (Eppendorf of North America, NY, USA).
Screening of S. aureus promoter-lux reporters.

Screening of S. aureus promoter-lux clones was performed according to the published protocol21. In brief, a single colony of each luminescent S. aureus clone was
re-suspended in sterile water, diluted 1000-fold into 0.7% (w/v) agar and spread evenly across the surface of
NYEC plates. Paper discs (232189, BD Biosciences, NJ, USA) containing 2 μg of HMPC were placed onto the
plates and incubated at 37 °C for 20 h. Discs containing DMSO were added to plates as controls. Luminescence
was detected with an IVIS Lumina III In Vivo Imaging System (Perkin Elmer, MA, USA).

Assessment of HMPC binding to DNA. To assess HMPC binding to eukaryotic DNA, UV-visible spectra
were recorded on a Beckman DU 80 spectrophotometer54 using a quartz micro cell cuvette. Measurements were
obtained for calf thymus DNA in Tris—HCl buffer (pH 7.2, 10 mM) in the presence or absence of HMPC (20 μg/
ml) over the wavelength range of 290–400 nm (10 nm increments), as described previously54. We also assessed
the effect of DNA on the zone of growth inhibition of S. aureus produced by HMPC using calf thymus DNA and
genomic DNA from S. aureus MW2. The experiment with calf thymus DNA was performed as described previously55 with minor modifications. Solutions of HMPC (5 μg-25 μg) were mixed with 5 μg calf thymus DNA and
incubated for 10 min at RT before being spotted onto discs (232189, BD Biosciences, NJ, USA) and overlaid onto
S. aureus MW2 lawns growing on MHA medium. The zones of growth inhibition were visually observed and
measured with a ruler after incubation at 37 °C for 21 h. Experiments were performed twice.
To assess HMPC binding to prokaryotic DNA, solutions containing 10–25 μg of HMPC were left untreated or
were mixed with 5 μg S. aureus MW2 genomic DNA. Solutions were then spotted onto filter paper discs and overlaid onto a TSA plate containing MW2 bacteria in a soft agar overlay. After overnight incubation at 37 °C, zones
of inhibition were measured with a ruler. Finally, an electrophoretic mobility shift assay (EMSA) was conducted
by incubating S. aureus MW2 genomic DNA (500 ng) with DMSO alone or with 5 μg HMPC dissolved in DMSO,
and then running the mixtures on a 1% agarose gel at 70 volts for 4 hours. The gel was then stained with 0.5 μg/ml
ethidium bromide to visualize the DNA bands.
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Determination of the frequency of rifampicin-resistant mutants. An overnight culture of S. aureus

MW2 was diluted to the McFarland standard 0.5 in TSB medium and grown until mid-log phase. Bacteria were
serially diluted 10-fold in TSB medium and aliquots were plated on either rifampicin-containing TSA plates, to
determine the number of resistant mutants, or non-selective plates, to determine the number of CFU/ml. The
mutation frequency was calculated as the ratio of rifampicin-resistant mutants to total cells in the population, as
described previously56,57.

Selection of HMPC-resistant S. aureus MW2 mutants.

Sequential passaging in liquid medium to
develop HMPC-resistant isolates was performed as previously described24. For the first round of selection, an
overnight culture of S. aureus MW2 was diluted to an optical density at 600 nm (OD600) of 0.1 in TSB medium
supplemented with 1xMIC, 2xMIC, and 4xMIC HMPC (in triplicate). After 24 h of incubation at 37 °C with
shaking at 200 rpm, the tube with the highest HMPC concentration that contained visible bacterial growth
(OD600 > 0.1) was used to dilute the bacterial culture to OD600 = 0.1 for the next round of selection, and to determine the concentrations of HMPC to be tested. The MIC of cultures derived from strains grown in the highest
HMPC concentration was used to confirm resistance to the compound.

Whole genome sequencing and variant calling. Genomic DNA from overnight cultures of S. aureus
MW2 control and resistant strains was isolated using a DNeasy Blood and Tissue kit (Qiagen, CA, USA) using the
manufacturer’s protocol. A paired-end sequencing library (2x250 bp) was prepared for each DNA sample using a
Nextera XT kit (Illumina, CA, USA). Libraries were pooled and sequenced using an Illumina HiSeq. 2500 (MEEI
Ocular Genomics Institute, Boston, MA). Variants were identified using Pilon58, by mapping sequencing reads
to the closed S. aureus MW2 genome (GenBank accession GCA_001019125.1). Unique variants found in the
selected strains that were absent in control strains are reported. Additional low-frequency mutations in mgrA and
fmtC were identified using CLC Genomics Workbench version 7.0 (CLC bio, MA, USA).
Minimum inhibitory concentration of HMPC in the presence of an efflux pump inhibitor.

The
effect of the efflux pump inhibitor thioridazine on S. aureus MW2 susceptibility to HMPC was evaluated using
the 2-fold microdilution method in the presence of a sub-inhibitory concentrations of thioridazine (0.5 μg/ml),
as previously described41.

Triton X-100 – induced autolysis assay under static conditions.

Overnight cultures of S. aureus
strains were diluted to an optical density at 600 nm (OD600) of 0.1 in TSB with 0.05% Triton X-100. Cells were
incubated in 96-well plates at 37 °C without shaking, and optical densities were recorded hourly for 8 hours.

Mammalian cell cytotoxicity assay.

Growth media and other cell culture reagents were obtained from
Thermo Fisher Scientific. HKC-8 immortalized human renal proximal tubular epithelial cells were maintained in
Dulbecco’s Modified Eagle Medium/Nutrient F-12 Ham (DMEM/F12) supplemented with 10% FBS. The HepG2
liver cells were from ATCC (HB-8065) and cells were grown in Eagle’s Minimum Essential Medium (EMEM)
supplemented with 10% FBS. HKC-8 and HepG2 cells were cultured in 96 - well tissue culture plates at a density
of 10000 cells/well, followed by the addition of HMPC in various concentrations or control medium (DMEM/
F12 or EMEM with 0.01% DMSO). The cells were subsequently incubated for 24 hours prior to the application of
Cell Proliferation Reagent WST-1 (WST-1 reagent Roche, IN, USA), according to the manufacturer’s instructions.
Each concentration of HMPC was tested in triplicates and the experiment was repeated twice.

Hemolysis assay.

Human erythrocytes were purchased from Rockland Immunochemicals (Human red
blood cells 10% washed pooled cells, R407-0050). The assay was performed as described59 in triplicates and
repeated twice.

References

1. Lowy, F. D. Staphylococcus aureus infections. N. Engl. J. Med. 339, 520–532, https://doi.org/10.1056/nejm199808203390806 (1998).
2. Archer, G. L. Staphylococcus aureus: a well-armed pathogen. Clin. Infect. Dis. 26, 1179–1181 (1998).
3. Dayan, G. H. et al. Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention. Expert review
of vaccines 15, 1373–1392, https://doi.org/10.1080/14760584.2016.1179583 (2016).
4. Prevention, C. f. D. C. a. Antiobiotic Resistance thtreats in the United States, 2013, https://www.cdc.gov/drugresistance/threatreport-2013/index.html (2013).
5. Bui, L. M., Conlon, B. P. & Kidd, S. P. Antibiotic tolerance and the alternative lifestyles of Staphylococcus aureus. Essays Biochem. 61,
71–79, https://doi.org/10.1042/ebc20160061 (2017).
6. Didelot, X., Walker, A. S., Peto, T. E., Crook, D. W. & Wilson, D. J. Within-host evolution of bacterial pathogens. Nat. Rev. Microbiol.
14, 150–162, https://doi.org/10.1038/nrmicro.2015.13 (2016).
7. Chang, H. H. et al. Origin and proliferation of multiple-drug resistance in bacterial pathogens. Microbiol. Mol. Biol. Rev. 79,
101–116, https://doi.org/10.1128/MMBR.00039-14 (2015).
8. Sun, F. et al. Targeting MgrA-mediated virulence regulation in Staphylococcus aureus. Chem. Biol. 18, 1032–1041, https://doi.
org/10.1016/j.chembiol.2011.05.014 (2011).
9. Hu, Q., Peng, H. & Rao, X. Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus
aureus. Front. Microbiol. 7, 1601, https://doi.org/10.3389/fmicb.2016.01601 (2016).
10. Chang, S. et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. The New England
journal of medicine 348, 1342–1347, https://doi.org/10.1056/NEJMoa025025 (2003).
11. Rossi, F. et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N. Engl. J. Med. 370, 1524–1531,
https://doi.org/10.1056/NEJMoa1303359 (2014).
12. de Niederhausern, S. et al. Vancomycin-resistance transferability from VanA enterococci to Staphylococcus aureus. Curr. Microbiol.
62, 1363–1367, https://doi.org/10.1007/s00284-011-9868-6 (2011).
13. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new
antibiotics (2017).

SCIENtIfIC ReporTs | (2018) 8:7062 | DOI:10.1038/s41598-018-25571-w

10

www.nature.com/scientificreports/
14. Moy, T. I. et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem. Biol. 4, 527–533,
https://doi.org/10.1021/cb900084v (2009).
15. Rajamuthiah, R. et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus.
PLoS One 9, e89189, https://doi.org/10.1371/journal.pone.0089189 (2014).
16. Arvanitis, M., Glavis-Bloom, J. & Mylonakis, E. C. elegans for anti-infective discovery. Curr. Opin. Pharmacol. 13, 769–774, https://
doi.org/10.1016/j.coph.2013.08.002 (2013).
17. Conery, A. L., Larkins-Ford, J., Ausubel, F. M. & Kirienko, N. V. High-throughput screening for novel anti-infectives using a C.
elegans pathogenesis model. Curr. Protoc. Chem. Biol. 6, 25–37, https://doi.org/10.1002/9780470559277.ch130160 (2014).
18. Kong, C., Tan, M. W. & Nathan, S. Orthosiphon stamineus protects Caenorhabditis elegans against Staphylococcus aureus infection
through immunomodulation. Biol Open 3, 644–655, https://doi.org/10.1242/bio.20148334 (2014).
19. Rice, L. B. Progress and challenges in implementing the research on ESKAPE pathogens. Infect. Control Hosp. Epidemiol. 31(Suppl
1), S7–10, https://doi.org/10.1086/655995 (2010).
20. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical infectious
diseases: an official publication of the Infectious Diseases Society of America 48, 1–12, https://doi.org/10.1086/595011 (2009).
21. Mesak, L. R., Qi, S., Villanueva, I., Miao, V. & Davies, J. Staphylococcus aureus promoter-lux reporters for drug discovery. J. Antibiot.
(Tokyo) 63, 492–498, https://doi.org/10.1038/ja.2010.74 (2010).
22. Mesak, L. R., Yim, G. & Davies, J. Improved lux reporters for use in Staphylococcus aureus. Plasmid 61, 182–187, https://doi.
org/10.1016/j.plasmid.2009.01.003 (2009).
23. Dhanalakshmi Nair, G. M. et al. L. Cheung. Whole-Genome Sequencing of Staphylococcus aureus Strain RN4220, a Key Laboratory
Strain Used in Virulence Research, Identifies Mutations That Affect Not Only Virulence Factors but Also the Fitness of the Strain. J.
Bacteriol. 193, 2332–2335 (2011).
24. Palmer, K. L., Daniel, A., Hardy, C., Silverman, J. & Gilmore, M. S. Genetic basis for daptomycin resistance in enterococci.
Antimicrob. Agents Chemother. 55, 3345–3356, https://doi.org/10.1128/aac.00207-11 (2011).
25. Luong, T. T., Newell, S. W. & Lee, C. Y. Mgr, a novel global regulator in Staphylococcus aureus. J. Bacteriol. 185, 3703–3710 (2003).
26. Luong, T. T., Dunman, P. M., Murphy, E., Projan, S. J. & Lee, C. Y. Transcription Profiling of the mgrA Regulon in Staphylococcus
aureus. J. Bacteriol. 188, 1899–1910, https://doi.org/10.1128/jb.188.5.1899-1910.2006 (2006).
27. Baba, T. et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359, 1819–1827 (2002).
28. Crosby, H. A. et al. The Staphylococcus aureus Global Regulator MgrA Modulates Clumping and Virulence by Controlling Surface
Protein Expression. PLoS Pathog. 12, e1005604, https://doi.org/10.1371/journal.ppat.1005604 (2016).
29. Ingavale, S. S., Van Wamel, W. & Cheung, A. L. Characterization of RAT, an autolysis regulator in Staphylococcus aureus. Mol.
Microbiol. 48, 1451–1466 (2003).
30. Ingavale, S., van Wamel, W., Luong, T. T., Lee, C. Y. & Cheung, A. L. Rat/MgrA, a regulator of autolysis, is a regulator of virulence
genes in Staphylococcus aureus. Infect. Immun. 73, 1423–1431, https://doi.org/10.1128/iai.73.3.1423-1431.2005 (2005).
31. Grinholc, M. et al. Fine-tuning recA expression in Staphylococcus aureus for antimicrobial photoinactivation: importance of photoinduced DNA damage in the photoinactivation mechanism. Appl. Microbiol. Biotechnol. 99, 9161–9176, https://doi.org/10.1007/
s00253-015-6863-z (2015).
32. Miller, C. et al. SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 305, 1629–1631,
https://doi.org/10.1126/science.1101630 (2004).
33. Cuirolo, A., Plata, K. & Rosato, A. E. Development of homogeneous expression of resistance in methicillin-resistant Staphylococcus
aureus clinical strains is functionally associated with a beta-lactam-mediated SOS response. J. Antimicrob. Chemother. 64, 37–45,
https://doi.org/10.1093/jac/dkp164 (2009).
34. Bronner, S., Monteil, H. & Prevost, G. Regulation of virulence determinants in Staphylococcus aureus: complexity and applications.
FEMS Microbiol. Rev. 28, 183–200, https://doi.org/10.1016/j.femsre.2003.09.003 (2004).
35. Tsai, Y. T. et al. Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor
Combination Therapy. Cancer Res. 75, 3568–3582, https://doi.org/10.1158/0008-5472.can-14-3264 (2015).
36. Cheung, A. L., Bayer, A. S., Zhang, G., Gresham, H. & Xiong, Y. Q. Regulation of virulence determinants in vitro and in vivo in
Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 40, 1–9 (2004).
37. Cheung, A. L., Nishina, K. A., Trotonda, M. P. & Tamber, S. The SarA protein family of Staphylococcus aureus. Int. J. Biochem. Cell
Biol. 40, 355–361, https://doi.org/10.1016/j.biocel.2007.10.032 (2008).
38. Truong-Bolduc, Q. C., Dunman, P. M., Strahilevitz, J., Projan, S. J. & Hooper, D. C. MgrA Is a Multiple Regulator of Two New Efflux
Pumps in Staphylococcus aureus. J. Bacteriol. 187, 2395–2405, https://doi.org/10.1128/jb.187.7.2395-2405.2005 (2005).
39. Truong-Bolduc, Q. C., Zhang, X. & Hooper, D. C. Characterization of NorR protein, a multifunctional regulator of norA expression
in Staphylococcus aureus. J. Bacteriol. 185, 3127–3138 (2003).
40. Kaatz, G. W., Thyagarajan, R. V. & Seo, S. M. Effect of promoter region mutations and mgrA overexpression on transcription of
norA, which encodes a Staphylococcus aureus multidrug efflux transporter. Antimicrob. Agents Chemother. 49, 161–169, https://doi.
org/10.1128/aac.49.1.161-169.2005 (2005).
41. Santos Costa, S., Viveiros, M., Rosato, A. E., Melo-Cristino, J. & Couto, I. Impact of efflux in the development of multidrug resistance
phenotypes in Staphylococcus aureus. BMC Microbiol. 15, 232, https://doi.org/10.1186/s12866-015-0572-8 (2015).
42. Costa, S. S., Viveiros, M., Amaral, L. & Couto, I. Multidrug Efflux Pumps in Staphylococcus aureus: an Update. Open Microbiol. J. 7,
59–71, https://doi.org/10.2174/1874285801307010059 (2013).
43. Kristiansen, M. M. et al. Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to
oxacillin in vitro. Int. J. Antimicrob. Agents 22, 250–253 (2003).
44. Chen, P. R. et al. An oxidation-sensing mechanism is used by the global regulator MgrA in Staphylococcus aureus. Nat. Chem. Biol.
2, 591–595, https://doi.org/10.1038/nchembio820 (2006).
45. Komatsuzawa, H. et al. Cloning and sequencing of the gene, fmtC, which affects oxacillin resistance in methicillin-resistant
Staphylococcus aureus. FEMS Microbiol. Lett. 203, 49–54 (2001).
46. Oku, Y., Kurokawa, K., Ichihashi, N. & Sekimizu, K. Characterization of the Staphylococcus aureus mprF gene, involved in
lysinylation of phosphatidylglycerol. Microbiology 150, 45–51, https://doi.org/10.1099/mic.0.26706-0 (2004).
47. Nishi, H., Komatsuzawa, H., Fujiwara, T., McCallum, N. & Sugai, M. Reduced content of lysyl-phosphatidylglycerol in the
cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, in
Staphylococcus aureus. Antimicrob. Agents Chemother. 48, 4800–4807, https://doi.org/10.1128/aac.48.12.4800-4807.2004 (2004).
48. Slavetinsky, C. J., Peschel, A. & Ernst, C. M. Alanyl-phosphatidylglycerol and lysyl-phosphatidylglycerol are translocated by the same
MprF flippases and have similar capacities to protect against the antibiotic daptomycin in Staphylococcus aureus. Antimicrob. Agents
Chemother. 56, 3492–3497, https://doi.org/10.1128/aac.00370-12 (2012).
49. Slavetinsky, C., Kuhn, S. & Peschel, A. Bacterial aminoacyl phospholipids - Biosynthesis and role in basic cellular processes and
pathogenicity. Biochim. Biophys. Acta, https://doi.org/10.1016/j.bbalip.2016.11.013 (2016).
50. Kuhn, S., Slavetinsky, C. J. & Peschel, A. Synthesis and function of phospholipids in Staphylococcus aureus. Int. J. Med. Microbiol.
305, 196–202, https://doi.org/10.1016/j.ijmm.2014.12.016 (2015).
51. Mishra, N. N. et al. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus
strains: relative roles of mprF and dlt operons. PLoS One 9, e107426, https://doi.org/10.1371/journal.pone.0107426 (2014).

SCIENtIfIC ReporTs | (2018) 8:7062 | DOI:10.1038/s41598-018-25571-w

11

www.nature.com/scientificreports/
52. Schenk, S. & Laddaga, R. A. Improved method for electroporation of Staphylococcus aureus. FEMS Microbiol. Lett. 73, 133–138
(1992).
53. Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration
(MIC) of antimicrobial substances. Nat. Protoc. 3, 163–175, https://doi.org/10.1038/nprot.2007.521 (2008).
54. Rehman, S. U. et al. Interaction of 6 mercaptopurine with calf thymus DNA–deciphering the binding mode and photoinduced DNA
damage. PLoS One 9, e93913, https://doi.org/10.1371/journal.pone.0093913 (2014).
55. Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455–459, https://doi.org/10.1038/
nature14098 (2015).
56. Mick, V. et al. Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant
Staphylococcus aureus clone ST228, Spain. BMC Microbiol. 10, 68, https://doi.org/10.1186/1471-2180-10-68 (2010).
57. Pope, C. F., O’Sullivan, D. M., McHugh, T. D. & Gillespie, S. H. A practical guide to measuring mutation rates in antibiotic resistance.
Antimicrob. Agents Chemother. 52, 1209–1214, https://doi.org/10.1128/aac.01152-07 (2008).
58. Walker, B. J. et al. Pilon: An Integrated Tool for Comprehensive Microbial Variant Detection and Genome Assembly Improvement.
PLoS ONE 9(11), e112963 (2014).
59. Evans, B. C. et al. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic
delivery of biomacromolecular drugs. J Vis Exp, e50166, https://doi.org/10.3791/50166 (2013).
60. Garsin, D. A. et al. A simple model host for identifying Gram-positive virulence factors. Proc. Natl. Acad. Sci. USA 98, 10892–10897,
https://doi.org/10.1073/pnas.191378698 (2001).
61. Rahme, L. G. et al. Common virulence factors for bacterial pathogenicity in plants and animals. Science 268, 1899–1902 (1995).

Acknowledgements

This work was supported by P01 grant AI083214 to Eleftherios Mylonakis. Daria Van Tyne is supported by grant
EY028222 from the National Institutes of Health. The authors especially thank Alex R. Horswill for providing
mgrA mutants in S. aureus MW2. The authors also thank David C. Hopper and Que Chi Truong-Bolduc for their
participation in project discussions and valuable suggestions, Lance D. Dworkin and Rujun Gong for providing
HKC-8 cells, and Beth B. Fuchs for providing S. aureus clinical isolates.

Author Contributions

E.M. supervised the work, edited manuscript and provided funding. T.J. performed and analyzed experiments
except DNA sequencing and analysis, killing curve experiment, and experiments shown in Supplementary
Figures S1 and S3, which were done by D.V.T., who also edited the manuscript. lux-promoter screening was
performed R.F.C., B.K. performed HepG2 viability assay. T.J. wrote the manuscript. M.S.G. supervised the work
of D.V.T. N.L.F. performed the analysis of MgrA mutations. M.J.K. is a collaborator.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-25571-w.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2018

SCIENtIfIC ReporTs | (2018) 8:7062 | DOI:10.1038/s41598-018-25571-w

12

